153 related articles for article (PubMed ID: 31974828)
1. Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting.
Kullar R; Puzniak LA; Swindle JP; Lodise T
Infect Dis Ther; 2020 Mar; 9(1):107-117. PubMed ID: 31974828
[TBL] [Abstract][Full Text] [Related]
2. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
Prokocimer P; De Anda C; Fang E; Mehra P; Das A
JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
[TBL] [Abstract][Full Text] [Related]
3. Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.
De Anda C; Anuskiewicz S; Prokocimer P; Vazquez J
Medicine (Baltimore); 2017 Dec; 96(52):e9163. PubMed ID: 29384903
[TBL] [Abstract][Full Text] [Related]
4. Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series.
Shlyapnikov S; Jauregui A; Khachatryan NN; Kurup A; de la Cabada-Bauche J; Leong HN; Li L; Wilcox MH
Infect Dis Ther; 2018 Sep; 7(3):387-399. PubMed ID: 30003513
[TBL] [Abstract][Full Text] [Related]
5. Economic burden and secondary complications of influenza-related hospitalization among adults in the US: a retrospective cohort study.
Hu T; Miles AC; Pond T; Boikos C; Maleki F; Alfred T; Lopez SMC; McGrath L
J Med Econ; 2024; 27(1):324-336. PubMed ID: 38343288
[TBL] [Abstract][Full Text] [Related]
6. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.
Lodise TP; Fang E; Minassian SL; Prokocimer PG
Antimicrob Agents Chemother; 2014 Dec; 58(12):7198-204. PubMed ID: 25246392
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections.
Bradley JS; Antadze T; Ninov B; Tayob MS; Broyde N; Butterton JR; Chou MZ; De Anda CS; Kim JY; Sears PS
Pediatr Infect Dis J; 2021 Mar; 40(3):238-244. PubMed ID: 33395210
[TBL] [Abstract][Full Text] [Related]
8. Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease.
Bell EJ; Yu J; Bhatt V; Bunner SH; Lal LS; Galvin J; Weisdorf D
Transplant Cell Ther; 2022 Oct; 28(10):707.e1-707.e7. PubMed ID: 35483620
[TBL] [Abstract][Full Text] [Related]
9. Real-world retrospective analysis of patient characteristics, healthcare resource utilization, costs, and treatment patterns among unvaccinated adults with COVID-19 diagnosed in outpatient settings in the United States.
Scott A; Chambers R; Reimbaeva M; Atwell J; Baillon-Plot N; Draica F; Tarallo M
J Med Econ; 2022; 25(1):287-298. PubMed ID: 35114896
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Outpatient and Inpatient Antibiotic Treatment Patterns and Health Care Costs of Patients with Complicated Urinary Tract Infections.
Turner RM; Wu B; Lawrence K; Hackett J; Karve S; Tunceli O
Clin Ther; 2015 Sep; 37(9):2037-47. PubMed ID: 26212569
[TBL] [Abstract][Full Text] [Related]
11. Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: a retrospective claims data analysis.
Wattanakamolkul K; Nakayama Y
J Med Econ; 2022; 25(1):870-879. PubMed ID: 35703058
[TBL] [Abstract][Full Text] [Related]
12. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
13. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
Bell CF; Blauer-Peterson C; Mao J
J Manag Care Spec Pharm; 2021 Sep; 27(9):1249-1259. PubMed ID: 34165321
[No Abstract] [Full Text] [Related]
14. Inhaled Corticosteroid-Containing Treatment Escalation and Outcomes for Patients with Asthma in a U.S. Health Care Organization.
Bengtson LGS; Yu Y; Wang W; Cao F; Hulbert EM; Wolbeck R; Elliott CA; Buikema AR
J Manag Care Spec Pharm; 2017 Nov; 23(11):1149-1159. PubMed ID: 29083972
[TBL] [Abstract][Full Text] [Related]
15. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
[TBL] [Abstract][Full Text] [Related]
16. Burden of illness among patients with dementia-related psychosis.
Frazer M; Abler V; Halpern R; Skoog B; Rashid N
J Manag Care Spec Pharm; 2021 Mar; 27(3):367-378. PubMed ID: 33645238
[No Abstract] [Full Text] [Related]
17. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials.
Moran GJ; De Anda C; Das AF; Green S; Mehra P; Prokocimer P
Infect Dis Ther; 2018 Dec; 7(4):509-522. PubMed ID: 30242736
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
Bell CF; Ajmera MR; Meyers J
Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
[TBL] [Abstract][Full Text] [Related]
20. Reduced mortality, complications, and economic burden among medicare beneficiaries receiving influenza antivirals.
Best JH; Reddy SR; Chang E; Bognar K; Tarbox MH; Cagas SE; Seetasith A
J Med Econ; 2024; 27(1):240-252. PubMed ID: 38294309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
